University of Cincinnati
09/25/2026 | Press release | Distributed by Public on 09/24/2026 22:37
UC hematology researcher to study bone complications in sickle cell disease
UC hematology researcher to study bone complications in sickle cell disease
Role of inflammation under investigation with prestigious grant funding
5 minute read September 25, 2026 Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Print Story Like
September is National Sickle Cell Awareness Month, and a University of Cincinnati College of Medicine hematology researcher has received new grant funding to study one of the disease's painful, under-recognized complications: bone damage.
iStock/BojanMirkovic.
Jahnavi Gollamudi, MD, a research assistant professor in the Division of Hematology and Oncology within the Department of Internal Medicine, has received a National Institutes of Health/National Center for Advancing Translational Sciences (NCATS) Physician Scientist Award (K12), which includes a grant valued at more than $400,000 disbursed over the next two years to support her research on how bone cells promote bone pain in people with sickle cell disease. She also received an American Society of Hematology (ASH) 2026 Scholar Award - a competitive $150,000 research grant - to study factors driving bone complications in sickle cell disease. Both awards underscore a strong early-career trajectory for Gollamudi.
What is sickle cell disease?
iStock/tassel78.
Sickle cell disease (SCD) affects about 100,000 people in the United States. In people with SCD, red blood cells become rigid and deform into a crescent or sickle shape. Sickled cells die prematurely and often become lodged in small blood vessels, restricting blood flow and causing serious health problems throughout the body. Many people may know about anemia in sickle cell disease, but bone complications are less frequently discussed.
Bone complications in sickle cell disease patients
"Those with sickle cell disease tend to develop early-onset osteoporosis, which weakens bones and makes them brittle. They also develop compression fractures and avascular necrosis, which is the death of bone tissue caused by a temporary or permanent loss of blood supply," said Gollamudi. "We also know red blood cell disorders, particularly sickle cell disease, involve significant inflammation. Our research will investigate how this inflammation can lead to bone complications and whether inflammatory markers can help predict who is at higher risk, potentially enabling earlier intervention."
She will also explore how bone complications, and particularly bone cells, cause bone pain in patients with sickle cell disease.
"Individuals with sickle cell disease experience chronic musculoskeletal pain, which markedly diminishes their quality of life," said Gollamudi. "The goal of this project is to identify if bone cells are drivers for musculoskeletal pain."
Currently, there are no targeted pain therapies, and opioid treatments have limited efficacy, Gollamudi said. Building on her findings about the role of inflammation in bone complications, her research will examine whether treatments already approved by the U.S. Food and Drug Administration can be leveraged to treat chronic musculoskeletal pain.
"We think there are FDA-approved medications already on the market that could be used to treat bone complications and bone pain in patients with sickle cell disease," said Gollamudi.
Jahnavi Gollamudi, MD, reviews bone images on a computer screen in the Hyacinth Lab. Photo/Connor Boyle/UC Marketing + Brand.
Mentorship
Gollamudi currently conducts her research in the lab of her mentor, Hyacinth Hyacinth, MD, PhD, a professor in the Department of Neurology and Rehabilitation Medicine. The Hyacinth lab focuses on sickle cell disease, including its impact on stroke risk, and researchers there investigate a range of sickle cell disease complications.
Another UC mentor, Michael Jankowski, PhD, a professor in the Department of Pediatrics and a member of Cincinnati Children's Division of Anesthesiology and its Pain Management Center, contributes expertise that's directly relevant to Gollamudi's investigation into chronic musculoskeletal pain in people with sickle cell disease.
Outside UC, Gollamudi has two additional mentors: Jane Little, MD, professor of medicine at the University of North Carolina at Chapel Hill and director of its comprehensive sickle cell disease program; and Lalitha Nayak, MD, an associate professor of medicine at Indiana University School of Medicine, specializing in the care of patients with complex bleeding and clotting disorders at the IU Melvin and Bren Simon Comprehensive Cancer Center Hematology Clinic.
"These are powerful women physician-scientists who have inspired me," said Gollamudi. "Their work in sickle cell disease and hematology has shaped how I approach both patient care and research, and I am grateful for their guidance."
Featured image at top: Jahnavi Gollamudi, MD, inside the CARE/Crawley building on the medical campus. Photo/Connor Boyle/UC Marketing + Brand.
Frequently asked questions about UC's sickle cell bone disease research:
What is the focus of Gollamudi's sickle cell research? right arrow down arrowShe is studying why people with sickle cell disease develop bone complications and whether inflammation markers can help predict who is at higher risk for bone disease.
Gollamudi received a $150,000 2026 Scholar Award from the American Society of Hematology, as well as support from an NIH K12 grant, to advance her early-career research in hematology.
Bone complications can be painful, disabling and difficult to treat. Understanding how inflammation contributes to bone damage could enable earlier detection, better monitoring and more targeted treatments for people living with sickle cell disease.
The next groundbreaking discovery
UC is a powerhouse of discovery and impact as a Carnegie 1 research institution. From pioneering medical research to transformative engineering and social innovation, our faculty and students drive progress that reaches across the world.
Tags
Related Stories
1
New Imaging Research & Development Center opens on UC's medical campus
May 28, 2026
The University of Cincinnati's new Imaging Research & Development Center on its Cincinnati medical campus brings UC, UC Health, Cincinnati Children's, GE HealthCare and JobsOhio together to advance MRI research and accelerate imaging innovation.
2
UC awarded $1.1 million grant to tailor AI use in medical education
January 16, 2026
The University of Cincinnati College of Medicine has been selected as a recipient of a $1.1 million American Medical Association (AMA) Transforming Lifelong Learning Through Precision Education grant.
3
Struggling with daily HIV meds?
March 23, 2026
For many people living with HIV, staying healthy depends on something deceptively simple: taking a pill every day. But for those navigating unstable housing, stigma, mental health challenges or addiction, that daily routine can be hard to maintain. As Yahoo!Health recently reported, a new study suggests there may be a better option.
University of Cincinnati published this content on September 25, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 25, 2026 at 04:37 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]